SIGYN THERAPEUTICS INC (SIGY) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2025, filed Nov 14, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the SIGY SEC filings page.
This page shows SIGYN THERAPEUTICS INC (SIGY) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue is not reported, while R&D and external financing support operations and liabilities overwhelm the company’s asset base.
In FY2024, operating cash outflow of$872K was nearly matched by financing inflow of$873K , so reported operations were funded mainly through outside capital rather than internally generated cash. R&D was$773K , close to the operating outflow, linking the cash need to continued development spending rather than a revenue-funded operating model.
The balance sheet’s structure is more important than conventional profitability ratios here: FY2024 liabilities of
From FY2022 to FY2024, liabilities increased while assets decreased, widening the balance-sheet deficit rather than reflecting simple operating expansion. The reported liquidity measure was only 0.2 months of the latest annual operating outflow, reinforcing that cash resources were limited relative to the reported spending pace.
Financial Health Signals
SIGYN THERAPEUTICS INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
SIGYN THERAPEUTICS INC's EBITDA was -$387K in Q3 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 52.1% from the same quarter a year earlier.
SIGYN THERAPEUTICS INC reported -$579K in net income in Q3 2025. This represents an increase of 51.7% from the same quarter a year earlier.
SIGYN THERAPEUTICS INC earned -$0.36 per diluted share (EPS) in Q3 2025. This represents an increase of 61.7% from the same quarter a year earlier. Against the prior quarter it is up 60.0%.
Not reported for Q3 2025.
Cash & Balance Sheet
SIGYN THERAPEUTICS INC held $86K in cash against $3.5M in long-term debt as of Q3 2025.
Not reported for Q3 2025.
Not reported for Q3 2025.
Margins & Returns
None of these metrics is reported for Q3 2025.
Capital Allocation
SIGYN THERAPEUTICS INC invested $30K in research and development in Q3 2025. This represents a decrease of 85.6% from the same quarter a year earlier. Against the prior quarter it is up 296.7%.
Not reported for Q3 2025.
Not reported for Q3 2025.
SIGY Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-Q | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $30K-85.6% | $7K-96.9% | $9K-96.2% | N/A | $206K-4.2% | $240K+9.7% | $233K+57.3% | N/A |
| SG&A Expenses | $307K-45.7% | N/A | $487K+35.5% | N/A | $565K+44.8% | $325K+2.4% | $360K+7.1% | N/A |
| Operating Income | -$387K+52.2% | N/A | -$546K+13.3% | N/A | -$808K-25.8% | -$603K-5.0% | -$630K-20.9% | N/A |
| EBITDA | -$387K+52.1% | N/A | -$545K+13.3% | N/A | -$807K-26.0% | -$601K-5.3% | -$628K-21.2% | N/A |
| Net Income | -$579K+51.7% | N/A | -$669K+11.8% | N/A | -$1.2M-32.2% | -$862K-19.3% | -$758K+43.5% | N/A |
| EPS (Basic) | -$0.36+61.7% | -$0.90-28.6% | -$0.42+32.3% | -$0.25+93.2% | -$0.94-14.6% | -$0.70-4.5% | -$0.62+55.4% | -$3.70-20.5% |
| EPS (Diluted) | -$0.36+61.7% | -$0.90-28.6% | -$0.42+32.3% | -$0.25+93.2% | -$0.94 | -$0.70 | -$0.62 | -$3.70 |
| Diluted Shares (Avg) | 2M+26.5% | 2M+29.7% | 2M+30.5% | N/A | 1M | 1M | 1M | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.
SIGY Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-Q | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $136K-68.3% | $52K-83.8% | $244K-24.4% | $214K-33.6% | $427K+10.4% | $320K-11.5% | $323K-51.0% | $322K-3.3% |
| Current Assets | $86K-68.2% | $2K-98.8% | $68K-49.3% | $21K-82.0% | $269K+59.4% | $146K+13.7% | $134K-67.4% | $118K+67.9% |
| Cash & Equivalents | $86K-48.1% | $459-99.1% | $13K-60.7% | $12K+3.9% | $165K+155.2% | $54K+127.0% | $33K-89.8% | $12K+39.9% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | N/A | N/A | N/A | N/A | $50K0.0% | $50K0.0% | $50K0.0% | $50K0.0% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $6.1M+39.1% | $5.5M+37.5% | $5.2M+19.4% | $4.7M+25.1% | $4.4M+9.8% | $4.0M+17.3% | $4.3M+44.5% | $3.7M+67.0% |
| Current Liabilities | $4.0M-6.7% | $5.5M+40.8% | $5.2M+21.7% | $4.6M+27.9% | $4.3M+11.9% | $3.9M+20.1% | $4.2M+49.5% | $3.6M+76.1% |
| Non-Current Liabilities | $2.1M+2660.3% | $0-100.0% | $38K-65.8% | $56K-55.4% | $75K-47.5% | $93K-41.4% | $110K-36.5% | $126K-32.6% |
| Long-Term Debt | $3.5M+77.9% | $2.5M+23.9% | $2.4M-13.7% | $2.0M-19.4% | $2.0M-47.3% | $2.0M-34.1% | $2.8M | $2.5M+10.0% |
| Total Equity | -$5.9M-50.8% | -$5.4M-48.1% | -$4.9M-23.0% | -$4.5M-30.6% | -$3.9M-9.7% | -$3.7M-20.7% | -$4.0M-71.4% | -$3.4M-79.3% |
| Retained Earnings | -$17.4M-22.7% | -$16.8M-29.6% | -$15.4M-26.9% | -$14.7M-29.5% | -$14.2M-39.3% | -$13.0M-40.0% | -$12.1M-41.7% | -$11.3M-57.6% |
Not reported in any period shown, so not listed: Accounts Receivable, Goodwill.
SIGY Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-Q | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$199K-21.7% | -$152K+16.6% | -$294K-25.0% | -$290K-126.9% | -$164K+55.0% | -$183K+44.4% | -$236K+58.1% | -$128K+71.7% |
| Depreciation & Amortization | $0-100.0% | $0-100.0% | $1K-10.5% | $1K-15.3% | $1K-32.4% | $1K-47.8% | $2K-41.8% | $2K-38.4% |
| Stock-Based Compensation | N/A | N/A | $50K+33.3% | N/A | N/A | N/A | $38K0.0% | N/A |
| Financing Cash Flow | $284K+3.4% | $140K-31.2% | $295K+15.0% | $138K+83.4% | $275K-32.1% | $204K+578.7% | $257K-70.7% | $75K-82.6% |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
SIGY Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$4.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| SIGYN THERAPEUTICS INC SIGY | FY2024 | N/A | N/A | N/A | $194K | — |
| BIOXYTRAN INC BIXT | FY2025 | N/A | -$2.1M | N/A | $2.6M | — |
| VAXXINITY INC A VAXX | FY2023 | N/A | -$56.9M | N/A | $13.9M | — |
Where SIGYN THERAPEUTICS INC Ranks
Frequently Asked Questions
How much debt does SIGYN THERAPEUTICS INC have?
As of fiscal year 2024, SIGYN THERAPEUTICS INC (SIGY) had $12K in cash and equivalents against $2.0M in long-term debt.
What is SIGYN THERAPEUTICS INC's operating cash flow?
SIGYN THERAPEUTICS INC (SIGY) recorded an outflow of $872K in operating cash flow during fiscal year 2024, representing cash used by core business activities.
What are SIGYN THERAPEUTICS INC's total assets?
SIGYN THERAPEUTICS INC (SIGY) had $214K in total assets as of fiscal year 2024, including both current and long-term assets.
How much does SIGYN THERAPEUTICS INC spend on research and development?
SIGYN THERAPEUTICS INC (SIGY) invested $773K in research and development during fiscal year 2024.
What is SIGYN THERAPEUTICS INC's current ratio?
SIGYN THERAPEUTICS INC (SIGY) had a current ratio of 0.00 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is SIGYN THERAPEUTICS INC's P/E ratio?
SIGYN THERAPEUTICS INC (SIGY) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $194K as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is SIGYN THERAPEUTICS INC's price-to-sales ratio?
SIGYN THERAPEUTICS INC (SIGY) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $194K as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does SIGYN THERAPEUTICS INC's liquidity compare with its operating cash outflow?
At the end of fiscal year 2024, SIGYN THERAPEUTICS INC (SIGY) held $12K in cash, cash equivalents and investments, and reported an operating cash outflow of $872K over that year. Dividing the one by the other, the reported balance equals about 0 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is SIGYN THERAPEUTICS INC's debt-to-equity ratio negative or not reported?
SIGYN THERAPEUTICS INC (SIGY) has negative shareholder equity of -$4.5M as of fiscal year 2024, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.